Zobrazeno 1 - 10 of 35 pro vyhledávání: '"Simona Mozzetti"'
1
Akademický článek
KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer
Autor: Marta De Donato, Gabriele Babini, Simona Mozzetti, Marianna Buttarelli, Alessandra Ciucci, Gloria Arduini, Maria Cristina De Rosa, Giovanni Scambia, Daniela Gallo
Publikováno v: Journal of Experimental & Clinical Cancer Research, Vol 39, Iss 1, Pp 1-17 (2020)
Abstract Background In spite of great progress in the surgical and clinical management, until now no significant improvement in overall survival of High-Grade Serous Ovarian Cancer (HGSOC) patients has been achieved. Important aspects for disease con
Externí odkaz: https://doaj.org/article/ab586b2c682642fb96a21119865ea0fb
Zobrazit plný text záznamu
5
Data from Paclitaxel Directly Binds to Bcl-2 and Functionally Mimics Activity of Nur77
Autor: Giovanni Scambia, Giuseppe Campiani, Caterina Fattorusso, Marco Persico, Daniela Gallo, Simona Mozzetti, Carlo Bertucci, Samanta Cimitan, Silvia Bartollino, Giuseppina Raspaglio, Lucia Cicchillitti, Cristiano Ferlini
We reported previously that Bcl-2 is paradoxically down-regulated in paclitaxel-resistant cancer cells. We reveal here that paclitaxel directly targets Bcl-2 in the loop domain, thereby facilitating the initiation of apoptosis. Molecular modeling rev
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34ead0c99825c487f3659a76bd107582
https://doi.org/10.1158/0008-5472.c.6499004
Zobrazit plný text záznamu
6
KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer
Autor: Giovanni Scambia, Gabriele Babini, Simona Mozzetti, Daniela Gallo, Maria Cristina De Rosa, Marianna Buttarelli, Alessandra Ciucci, Marta De Donato, Gloria Arduini
Publikováno v: Journal of experimental & clinical cancer research (Online) 39 (2020): 265. doi:10.1186/s13046-020-01775-9
info:cnr-pdr/source/autori:Marta De Donato 1 2, Gabriele Babini 3, Simona Mozzetti 2, Marianna Buttarelli 1 2, Alessandra Ciucci 1 2, Gloria Arduini 4, Maria Cristina De Rosa 5, Giovanni Scambia 2 3, Daniela Gallo 6 7/titolo:KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer/doi:10.1186%2Fs13046-020-01775-9/rivista:Journal of experimental & clinical cancer research (Online)/anno:2020/pagina_da:265/pagina_a:/intervallo_pagine:265/volume:39
Journal of Experimental & Clinical Cancer Research, Vol 39, Iss 1, Pp 1-17 (2020)
Journal of Experimental & Clinical Cancer Research : CR
Background In spite of great progress in the surgical and clinical management, until now no significant improvement in overall survival of High-Grade Serous Ovarian Cancer (HGSOC) patients has been achieved. Important aspects for disease control rema
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d8ece3d1e08b2b4e9f227f7a64ec035
https://pubmed.ncbi.nlm.nih.gov/33250051/
Zobrazit plný text záznamu
7
Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer
Autor: Giuseppina Raspaglio, Flavia Filippetti, Giovanni Scambia, Silvia Prislei, Cristiano Ferlini, Enrica Martinelli, Marisa Mariani, Gian Franco Zannoni, Marco Petrillo, Simona Mozzetti
Publikováno v: Scopus-Elsevier
Oncotarget
// Silvia Prislei 1 , Enrica Martinelli 1 , Gian Franco Zannoni 1, 2 , Marco Petrillo 1 , Flavia Filippetti 1 , Marisa Mariani 3 , Simona Mozzetti 1 , Giuseppina Raspaglio 1 , Giovanni Scambia 1 , Cristiano Ferlini 1, 3 1 Department of Obstetrics and
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84e3b0f9fd653146a6c0f820fd2aaf04
https://doi.org/10.18632/oncotarget.3943
Zobrazit plný text záznamu
8
Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib
Autor: Tiziana Servidei, Simona Mozzetti, Riccardo Riccardi, Cristiano Ferlini, Anna Riccardi
Publikováno v: International Journal of Cancer. 123:2939-2949
Deregulated signaling through the epidermal growth factor receptor (EGFR) is involved in chemoresistance. To identify the molecular determinants of sensitivity to the EGFR inhibitor gefitinib (Iressa, ZD1839) in chemoresistance, we compared the respo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcaced33a4fcf529ce25419933c5dd3f
https://doi.org/10.1002/ijc.23902
Zobrazit plný text záznamu
9
From plasma membrane to cytoskeleton: a novel function for semaphorin 6A
Autor: Marta De Donato, Giuseppina Raspaglio, Flavia Filippetti, Cristiano Ferlini, Giovanni Scambia, Lucia Cicchillitti, Simona Mozzetti, Silvia Prislei
Publikováno v: Molecular Cancer Therapeutics. 7:233-241
Class III β-tubulin (TUBB3) overexpression has been reported in ovary, lung, breast, and gastric cancer patients. Currently, no clinical drugs are available for a specific targeting of TUBB3, whereas the investigational drug IDN5390 specifically int
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5b6ebb0a2a9b5ee9607a648548241c8
https://doi.org/10.1158/1535-7163.mct-07-0390
Zobrazit plný text záznamu
10
Class III β-Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients
Autor: Cristiano Ferlini, Giovanni Scambia, Gabriella Ferrandina, Enrica Martinelli, Amelia Paglia, Simona Mozzetti, Valerio Gallotta, Gian Franco Zannoni
Publikováno v: Clinical Cancer Research. 12:2774-2779
Purpose: Overexpression of β III tubulin has been involved in paclitaxel resistance in several experimental models. We investigated the role of β III tubulin as predictor of clinical outcome in ovarian cancer patients given platinum/paclitaxel trea
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb1ebac8fada791c6c13ef5912157825
https://doi.org/10.1158/1078-0432.ccr-05-2715
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje